Emerging drugs for common conditions of sleepiness: obstructive sleep apnea and narcolepsy

  title={Emerging drugs for common conditions of sleepiness: obstructive sleep apnea and narcolepsy},
  author={Shannon S. Sullivan and C Guilleminault},
  journal={Expert Opinion on Emerging Drugs},
  pages={571 - 582}
Introduction: Obstructive sleep apnea (OSA) and narcolepsy are sleep disorders associated with high prevalence and high symptomatic burden including prominent sleepiness, daytime dysfunction and poor nocturnal sleep. Both have elevated risk of poor health outcomes. Current therapies are often underutilized, cumbersome, costly or associated with residual symptoms. Areas covered: This review covers current available therapies for OSA and narcolepsy as well as discusses areas for potential drug… 
Investigational therapies for the treatment of narcolepsy
JZP-110, with its distinct mechanism of action, would be a new therapeutic option for the treatment of EDS in narcolepsy in the coming years.
Understanding the burden of illness of excessive daytime sleepiness associated with obstructive sleep apnea: a qualitative study
Findings suggest that patients may be unaware that their symptoms could indicate OSA requiring evaluation and treatment, and even following diagnosis, EDS associated with OSA can continue to substantially affect HRQOL and daily functioning.
An approach to excessive daytime sleepiness in adults
The different potential causes of excessive daytime sleepiness in adults are discussed and an approach to management and referral in non-specialist settings is proposed, in particular how to identify disorders that require referral to secondary care.
Drug Therapy in Obstructive Sleep Apnea.
Impact of histaminergic H3 receptor antagonist on hypoglossal nucleus in chronic intermittent hypoxia conditions
It is revealed that the negative effects on the HN and TMN caused by CIH could be partly ameliorated by ciproxifan, which might open new perspectives for the development of pharmacological treatment for OSA.
Evaluation of surgical methods for sleep apnea and snoring
The safety and efficacy of treating snoring and OSA surgically surgically and the need for further studies on this and other treatments for obstructive sleep apnea are still being investigated.
Differenzialdiagnostik der Hypersomnie in der operativen Schlafmedizin – mehr als nur Schlafapnoe!
In der klinischen Versorgung von Patienten mit obstruktiver Schlafapnoe (OSA) nehmen Fachärzte für Hals‑, Nasen- und Ohrenheilkunde eine wichtige Rolle ein, insbesondere in der ambulanten Diagnostik
Traitement de la cataplexie
La presente invention concerne un procede de traitement de la cataplexie chez un sujet qui en a besoin, comprenant l'administration au sujet d'une quantite therapeutiquement efficace de certains


Effects of opioid, hypnotic and sedating medications on sleep-disordered breathing in adults with obstructive sleep apnoea.
Whether administration of sedative and hypnotic drugs exacerbates the severity of OSA or the 4% oxygen desaturation index (ODI) in people with known OSA is investigated to investigate.
A Practical Guide to the Therapy of Narcolepsy and Hypersomnia Syndromes
  • E. Mignot
  • Psychology, Medicine
  • 2012
New classifications now distinguish narcolepsy/hypocretin deficiency, a lifelong disorder with well-established diagnostic procedures and etiology, from other syndromes with hypersomnolence of unknown causes.
Complex Sleep Apnea
The majority of chemoreflex effects go unrecognized due to the bias toward obstructive sleep apnea’s current scoring criteria, and the power of multi-modality therapy should be harnessed for optimal outcomes.
Drug therapy for obstructive sleep apnoea in adults.
The use of drug therapy in the treatment of OSA was proposed as an alternative to CPAP in some patients with mild to moderate sleep apnoea and could be of value in patients intolerant of CPAP and many trials had methodological limitations.
Proof of Concept Trial of Dronabinol in Obstructive Sleep Apnea
Dronabinol treatment is safe and well-tolerated in OSA patients at doses of 2.5–10 mg daily and significantly reduces AHI in the short-term and should be confirmed in a larger study in order to identify sub-populations with OSA that may benefit from cannabimimetic pharmacologic therapy.
Innovative treatments for adults with obstructive sleep apnea
New treatments for OSA and associated complex sleep apnea are described, including laser-assisted uvulopalatoplasty, radiofrequency ablation, palatal implants, and electrical stimulation of the upper airway muscles.
Emerging therapies in narcolepsy-cataplexy.
This review discusses emerging therapies in the area of narcolepsy that include novel antidepressant or anticataplectic, wake-promoting, and hypnotic compounds, and reports on novel strategies designed to compensate for hypocretin deficiency and on the use of immunosupression at the time of narCOlepsy onset.
Narcolepsy with cataplexy
Defining phenotypic causes of obstructive sleep apnea. Identification of novel therapeutic targets.
It is confirmed that OSA is a heterogeneous disorder and abnormalities in nonanatomic traits are also present in most patients with OSA, and a three-point scale for weighting the relative contribution of the traits is proposed.
Epidemiology of obstructive sleep apnea: a population health perspective.
Evidence from methodologically strong cohort studies indicates that undiagnosed obstructive sleep apnea, with or without symptoms, is independently associated with increased likelihood of hypertension, cardiovascular disease, stroke, daytime sleepiness, motor vehicle accidents, and diminished quality of life.